Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Connect Biopharma Holdings Limited - Ordinary Shares (NQ:CNTB)

0.9104 -0.0296 (-3.15%)
Delayed Quote Updated: 1:34 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Connect Biopharma Holdings Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures ↗
Connect Biopharma (NASDAQ:CNTB) reported top-line results from its Seabreeze STAT Phase II study of rademikibart in patients experiencing acute exacerbations of chronic obstructive pulmonary disease,... 
Via MarketBeat
Top movers analysis one hour before the close of the markets on 2026-09-30: top gainers and losers in today's session. ↗
Via Chartmill
Discover the most active stocks in Wednesday's session. ↗
Via Chartmill
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
Which stocks are gapping on Wednesday? ↗
Via Chartmill
Wednesday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
Keep an eye on the top gainers and losers in Tuesday's session. ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation
From Connect Biopharma Holdings Limited
Via GlobeNewswire
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Touts Rademikibart’s Edge as SEABREEZE Data Looms in 2026 ↗
Connect Biopharma (NASDAQ:CNTB) Chief Executive Officer Barry Quart said the company’s rademikibart program continues to show a differentiated clinical and mechanistic profile as the company awaits... 
Via MarketBeat
News headline image
Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis
Expect to report topline data from both studies mid-2026 
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms
Via ACCESS Newswire
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Announces $20.2 Million Private Placement Financing
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026
From Connect Biopharma Holdings Limited
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.